Life Sciences Archive » December, 2019

Life Sciences - December, 2019

241 articles

• Hottest Legal Industry Guest Topics Of 2019
• Maryland Legislator Accused In Medical Pot Bribery Scheme
• Zetia Buyers' Lose Antitrust Claims Against Merck, Glenmark
• China Poised To Cut Hundreds Of Tariffs As Tensions Cool
• St. Louis Jury Clears J&J For Its 2nd Talc Win In A Week
• Feds Back Bayer's Bid To Undo $25M Monsanto Verdict
• Sanofi Latest To Tell Full Fed. Circ. Arthrex Changed The Law
• J&J Asks St. Louis Talc Jury To Stand Up For Corporations
• Biggest Developments Of 2019 In Antitrust Cases
• Ex-Genentech Workers Can't Ditch Trade Secret Charges
• 9th Circ. Told Attys Wrongly Sanctioned In Roundup Trial
• Taxation With Representation: Cleary, Skadden, Weil
• FDA Can Keep Regulating Genetically Modified Salmon
• Aegerion Sales Rep Found Guilty In $1.8M Drug Fraud
• This Year's Robust M&A Activity Will Likely Continue In 2020
• DEA, FDA Shut Down 44 Websites Selling Illegal Vapes
• Health & Life Sciences At The High Court: A Decade In Review
• Celgene Can't Shake Shareholder Suit Over Drug Trial
• The Trial Results That Made An Impact In 2019
• The Year In Cannabis Case Law: Major Pot Rulings From 2019
• Health Hires: Goodwin, Manatt, Garfunkel Wild
• PTAB Blocks Pharma Co.'s Repetitive Challenge To Iron Patent
• Senate Passes $1.4T Spending Package To Avert Shutdown
• Jones Day Reps PolyOne In $1.45B Deal For Clariant Unit
• House Approves Retooled North American Trade Accord
• Anthem Settles Class Action Over Autism Coverage Limits
• Scandals, Court Battles That Rocked New Jersey In 2019
• CBD Co.'s Atty Sanctioned In SEC Illicit Stock Sale Suit
• Ill. Insurance Coverage Cases From 2019 Settle Key Questions
• Roche Wants Russian Drug Co. Sanctioned In Antitrust Fight
• IP Pro Rejoins Harness Dickey In Boost To Texas Office
• The Top Bankruptcy Cases Of 2019
• Bayer Drops Trade Secret Suit Against Fired Scientist
• Vape Bans, Investigations And Hemp: 2019 In Pot Regulation
• Chancery Blocks Arbitration In Dow-Chemours Cleanup Battle
• Feds Want 15 Years For Convicted Insys Founder
• 5 Trends That Rocked The Legal Industry In 2019
• The Biggest Massachusetts Cases Of 2019
• The Biggest Patent Rulings Of 2019
• SEC Says Disbarred NY Attys Must Face PixarBio Merger Suit
• Two Agencies, Two 'Nascent Competitor' Merger Challenges
• J&J Exec Testifies FDA's Asbestos Finding Was Fluke
• Allergan Breast Implant Risk MDL Heading To NJ
• EU Clears Danaher $21B GE Biopharma Buy With Divestitures
• Boston Scientific Can't Nix $275M Merger With Device Maker
• Valeant Urges Fed. Circ. To Revive Lawsuit Over Jublia
• Ra Pharma's $2.1B Sale Hits Merger Review Snag At FTC
• Trade Group Urges Justices To Avoid Ark. Benefits Law Fight
• Chancellor Vexed By DuPont, Chemours Spinoff 'Chaos Derby'
• HHS Backs Drug Imports Amid White House Pressure
• Roundup Atty Charged With $200M Corporate Extortion Plot
• 3rd. Circ. Reverses GSK Win In Avandia Marketing Suit
• Fla. House, Cos. Back State's Medical Pot Licensing Rules
• Sens. Say DEA's 8B Opioid Production Quota Is Too High
• Feds Accuse CVS, Omnicare Of Prescription Fraud Scheme
• Impax Can't Use 'Unrelated Benefits,' AGs Tell 5th Circ.
• Ex-Theranos CEO Says Indictment 'Flunks The Constitution'
• Bipartisan Bill Would Have Pharmacies Fork Over Info To DEA
• Sacklers Withdrew $10B From Purdue, Bankruptcy Probe Says
• 10th Circ. Revives Medical Pot Inmate's Prison Challenge
• Judging A Book: Hinojosa Reviews 'Crimes And Punishments'
• Full Fed. Circ. Urged By All Sides To Rethink Arthrex
• Bausch Launches $1.25B Bond Offering To Pay For Settlement
• FTC Challenges Illumina's $1B DNA Sequencing Buy
• Eagle, Eli Lilly Drop Dueling Cancer Drug Patent Claims
• Kentucky Tax Talk: A New Governor's New Tax Ideas
• EpiPen Buyers Seek Class Status In ERISA Suit
• House Panel Greenlights Revised North American Trade Pact
• Loestrin Makers Settle Pay-For-Delay Suit With Direct Buyers
• 'Locality Lawsuits' Threaten The Civil Justice System
• $1.4T Gov't Funding Deal Has Border Wall, Generics, Pensions
• Roche-Spark $4.8B Merger Clears US, UK Regulatory Hurdles
• FDA Escapes Constitutional Challenge Of E-Cig Regulation
• Fed. Circ. Won't Revisit Patent Ruling On Weight Loss Pill
• Health Care Taxes Would Be Repealed Under Spending Plan
• Calif. Jury Finds J&J Not To Blame For Woman's Cancer
• Bausch Will Pay $1.2B To End Valeant-Era Stock Suit
• Actos Buyers Fight Takeda Appeal Bid In Drug Delay Case
• Cleary, Skadden Use Reverse Morris Trust To Forge $45B Co.
• Home Depot Wants Out Of Roundup Cancer Warning Suit
• Sienna Biopharma Seeks To Convert Its Ch. 11 Case
• Fed. Circ. Backs Amgen's $70M Patent Win Over Epogen
• Enablement For Life Sciences Patents Requires Sweat Equity
• Ill. Recreational Cannabis Law Brings Risks For Employers
• Ariz. Medical Pot Dispensary Can't Nix Rival's Registration
• Dems Urge USPTO To Probe Allegations Against Gilead
• Endo's $82.5M Deal In Suit Over Opioid Drug Gets Final OK
• Shareholders Sue Cardinal Health Execs Over Opioid Crisis
• Feds Press For Massive $306M Restitution In Insys Exec Trial
• North American Trade Pact Vote Could Come Wednesday
• Patients Say Rescheduling Pot Would Be A Step Backward
• Mass. Cannabis Vape Sales To Resume Under New Rules
• 5 Noncompete Rulings From 2019 Attorneys Should Know
• Taxation With Representation: Mayer, Sullivan, Covington
• Investor Sues To Block Foamix-Menlo All-Stock Merger
• Drug-Pricing Bill Threatens Robust Generics Industry
• Jury Says Kite Pharma Owes $752M For Infringing Patent
• 2020 Will Be A Year Of Decision For States
• Plaintiffs Experts' Cred At Stake In J&J Talc Trial Closings
• Jury Told Juno's Bid For $752M Patent Damages 'Just Crazy'
• Orexo Loses Bid For New Trial Over Teva's Suboxone Generic
• Calif. Judge Offers Tips On Winning Alice Invalidity Motions
• 2nd Circ. Says NY Opioid Fee Fight May Belong In State Court
• Ill. Latest To Sue Juul For Deceptively Marketing To Minors
• Rite Aid Beats FCA Suit Over Alleged Billing Scheme
• When DOJ Seeks Dismissals Of Life Sciences FCA Cases
• Senate Confirms Lung Cancer Doctor To Lead FDA
• Cleary Gottlieb Reps 3M In $650M Sale Of Drug Delivery Biz
• House Passes Democrats' Bill To Tamp Down Drug Prices
• High-Profile CEOs Urge 'Economy-Wide Action' On Paid Leave
• Calif. County DA Sharply Criticized In 2nd Circ.
• Investor Wants To Block $9.7B Novartis-Medicines Co. Deal
• Duke Asks Fed. Circ. For PTAB Redo On Muscle Treatment IP
• NJ Employment Legislation Had A Blockbuster Year
• Jury Told Patent Typo Shouldn't Get Kite Off $752M Hook
• Jones Day Says Pharma Client Owes $5.3M In Legal Bills
• Former NY Attys Want Out Of SEC's PixarBio Merger Suit
• US Trustee Says Jevic Kills Alston's $1M Deal In Imerys Ch. 11
• 3 Potential Speed Bumps For North American Trade Pact
• AstraZeneca Escapes Biotech Firm's $33.8M Lifted-Data Suit
• BakerHostetler Says Pharma Execs Can't Sue For Illegal Gains
• Fed. Circ. Affirms Actavis Infringed Anti-Nausea Drug Patent
• Momenta To Pay $35M To Exit Blood Clot Drug Antitrust Suit
• Calif. Fights Bid To Block Pay-For-Delay Law
• CBD Seller Says Farm Bill Tethers Case To Federal Court
• Pathologist Testifies He Found J&J Talc In Woman's Ovary
• CBD Co. Can't Escape Securities Class Action
• Ex-Novartis Exec Denied More Atty Fees In Whistleblower Row
• FTC Defends Impax Pay-For-Delay Ruling At 5th Circ.
• Fla. Court Won't Dismiss Pelvic Mesh Discovery Complaint
• Strategies To Maintain Privilege In Crisis Response Scenarios
• 9th Circ. Won't Revive Ex-Abbott Worker's Benefits Challenge
• The Rise Of Patent Wars In Europe's Gene Therapy Space
• Mass. PE Shop Omega Nabs $438M For Life Sciences Fund
• Supreme Court Strikes Down USPTO Atty Fee Rule
• Ex-Kite CEO Undermines Testimony Of Pharma Co.'s Founder
• Trade Deal Changes May Set New Course But Stir Discontent
• FDA's E-Cigarette Regulations Upheld By DC Circ.
• Cannabis Equipment Supplier Says It Was Stiffed On Bill
• NuVasive Tells 1st Circ. Noncompete Law Can't Help Ex-Rep
• FTC Looks Closer At $7.6B Bid To Forge Animal Health Giant
• Clinical Biopharma Sienna OK'd To Sell IP In Ch. 11
• 3 Firms Vie To Lead Chemours Stock-Drop Suit
• 3 Strategies To Manage Case Scope In ANDA Patent Litigation
• Proskauer Steers Perceptive Advisors' $210M Venture Fund
• GLAAD Urges Facebook To Drop Law Firms' HIV Drug Ads
• States Demand Purdue Fight Opioid Crisis With 9-Point Plan
• Revamped North American Trade Deal Set For Hill Vote
• FDA Wants Vape Group's Suit Over E-Cig Deadline Axed
• Juno's Expert Pegs Patent License Value At $752M In Kite Trial
• Ex-NY Rep. Chris Collins Settles SEC Insider Trading Claims
• SG Says Justices Should Use Athena Case To Redo Mayo
• Full Fed. Circ. Won't Review Celgene's Retroactive IPRs
• High Court Won't Review ITC's Refusal To Probe Ad Claims
• How To Ward Off Nonclient Suits Over Lawyers' Speech
• J&J Talc Supplier Imerys Asks For More Time On Ch. 11 Plan
• Cannabis Co. Sued For $150M Over Effort To Devalue Rival
• Navigating The Regulatory Environment For CBD Marketing
• Allergan Aims To Sink Suit Over Generics Antitrust Claims
• California Continues To Set State Environmental Law Trends
• Product Liability Claims Can Be A Global Threat To Cos.
• Ex-Health Care Co. Exec Pleads Guilty To Wire Fraud
• Covington, Skadden Steer Merck's $2.7B Deal For ArQule
• Counterfeit Good Policing In 2019 Was Redefined By Tech
• Workers Say Teva 401(k) Mismanagement Cost Them Millions
• Weil, Cooley Steer Sanofi's $2.5B Cancer Therapy Buy
• High Court Won't Hear Arizona's Opioid Suit Against Sacklers
• Fla. Asks High Court To Find Medical Pot Regs Constitutional
• Gilead Fights Monopoly Accusation Over HIV Prevention Drug
• Talc Jury Told They Could Save Lives By Ruling Against J&J
• Judge Says FDA Can't Regulate Imaging Liquid As Drug
• Fed. Circ. Judge Challenges USPTO Role In Biogen Appeal
• Calif. CBD Co. Sued After FDA Warning About Illegal Goods
• Justices Told Arthrex 'Uncertainty' Overshadows Immunity Bid
• Lieff Cabraser's Elizabeth Cabraser Talks About Opioids, VW
• New Talc Jury Gives J&J Chance To Stem Tide Of Legal Blows
• SEC Scores Early Win In Mass. Biotech CEO Fraud Suit
• 'Blocking Patent' Doctrine May Now Apply To All Technologies
• Fed. Circ. Vacates Samsung PTAB Win In Light Of Arthrex
• Jury Told Kite Wanted Sloan Kettering's Patients, Not Patent
• Doctor Linked To Insys Convicted On Kickback Charges
• Colo. CBD Vendor Latest To Face Class Action Over Legality
• Feds Can't Halt True Health's Ch. 11 Plan For Medicare Dispute
• Analysts Plead Not Guilty To Doctor's Office Ad Fraud Scheme
• Stinson Lands Former DOJ Health Care Fraud Enforcer
• Tufts Drops Sackler Name From Medical School Over Opioids
• Gov't Wants Justices To Tackle ERISA Preemption Case
• Allergan Says State Laws Doom Restasis Payors' Class Push
• Marijuana Magnate To Pay $4M In SEC Stock Boosting Suit
• Investors Say Aveo Pharma Can't Shake Stock-Drop Suit
• What Is A 'Reasonably Useful Form' For Production Of ESI?
• Big Data, Social Media Trigger More Life Science Mass Torts
• Bid Protest Spotlight: Tradeoffs, Venue, Ambiguity, Licenses
• Scrutiny Of Patient Assistance Program Funding Is Rising
• Fed. Circ.'s Arthrex Decision Should Apply Retroactively
• Jury Told 'Whole Field' Knows Kite Infringed Juno's Patent
• Hospital Groups Challenge HHS Pricing Transparency Rule
• Maine Says Hemp Rule Could Hold Back State's Farmers
• J&J Docs Show Its Talc Contained Asbestos, Expert Tells Jury
• Geico Accuses NY Pharmacy Of $1M No-Fault Insurance Fraud
• Full Fed. Circ. Passes On Enzo's Retroactive IPR Challenge
• Judge Holds Decision On Purdue Pharma CEO Bonus
• PTAB Allows J&J Unit To Amend Surgical Device Patent
• Insys Plan Disclosures OK'd On Road To Jan. Confirmation
• PTAB Rejects Agilent's Challenge Of Testing Kit Patent
• Innovative Collaborations Require Antitrust Flexibility
• IPO Benefits And Challenges For Early-Stage Biotech Cos.
• AstraZeneca Sells Rights To Embattled Bipolar Drug For $35M
• 'Puppet Master' Ran $1.8M Aegerion Drug Fraud, Jury Hears
• Possible Patent Typo Debated As Juno, Kite IP Trial Kicks Off
• 9th Circ. Revives Takeda Buyers' RICO Suit Over Actos Risk
• NJ Pharma Co. Settles Price-Fixing Charges For $3M
• 2 More CBD Cos. Accused Of Selling Illegal Products
• Rio Tinto Unit Tells Jury It Never Supplied J&J's Talc
• Attys Report Broad Support For Opioid MDL Negotiation Class
• Pittsburgh Utility Sued For Firing Man Over Medical Marijuana
• Patent Decision Highlights Cross-Appeal Considerations
• Pot Co. Harborside Takes $11M Tax Bill Battle To 9th Circ.
• Okla. Marijuana Ruling Underscores Broad Worker Projections
• Ex-Shkreli Employee Says Counterclaim Ignores Court Ruling
• Senate Committee Advances FDA Nominee
• Barnes & Thornburg Opens 3 Life Sciences IP Offices
• Ill. Cannabis Licensing Scheme Unconstitutional, Suit Says
• Insys Files New Ch. 11 Plan Reflecting Deal With DOJ, States
• FDA's Asbestos-In-Talc Finding Takes Stage In Latest J&J Trial
• Fed. Circ. Weighs Medical Device Indefiniteness Case
• Feds Seek Halt Of True Health Ch. 11 Plan Amid Medicare Row
• Covington, Fenwick Shape $3B Deal For California Drugmaker
• Walgreens Denies 'Fast Release' Pain Relievers Are Mislabeled
• Medical Supply Co. Slammed With Suit Over Data Breach
• Walgreens Is Latest To Sue Glumetza Makers Over Price Hikes
• CBD Co.'s Products Are Federally Illegal, Consumer Claims
• Cannabis Distributor Owes $6M For Hemp, Grower Says
• Pfizer Claims No Link To Generic-Drug Price-Fix Plot
• Mallinckrodt Hit With Cocaine Anesthetic Trade Secret Suit
• 1st Circ. Upholds Stripped Bonus For Fired Abiomed Exec
• Kisor May Be A New Dawn For Challenges To FDA Actions
• Covington-Led Immunotherapy Co. IFM Lands $56M Financing
• Proteon Therapeutics Investor Seeks To Halt $42M Merger
• Made In Canada: Why US Pot Is Tied To Its Northern Neighbor
• AGs Used Privileged Doc Again In Price-Fix Case: Pharma Co.